Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiagnosTSXV:ADK +4.40%25 EV-to-OCF is -14.25 as of Sep. 20, 2026. GuruFocus rates TSXV:ADK with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 685 Healthcare Providers & Services companies, Diagnos ranks better than 87.59% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Diagnos's Enterprise Value is C$56.97 Mil.
Diagnos's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was C$-4.00 Mil. Therefore, Diagnos's EV-to-OCF for today is -14.25.
The historical rank and industry rank for Diagnos's EV-to-OCF or its related term are showing as below:
TSXV:ADK'
s EV-to-OCF Range Over the Past 10 Years
Min: -29.55 Med: -10.05 Max: -1.41
Current: -14.37
During the past 13 years, the highest EV-to-OCF of Diagnos was -1.41. The lowest was -29.55. And the median was -10.05.
TSXV:ADK's EV-to-OCF is ranked better than 87.59% of 685
companies
in the Healthcare Providers & Services industry
Industry Median: 8.83
vs TSXV:ADK: -14.37
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-09-20), Diagnos's stock price is C$0.475.
Diagnos's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.041. Therefore, Diagnos's PE Ratio (TTM) for today is At Loss.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diagnos's share price for today is C$0.475.
Diagnos's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.041.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Diagnos EV-to-OCF Related Terms
Diagnos EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Diagnos's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Diagnos's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnos EV-to-OCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Diagnos's EV-to-OCF falls into.
Diagnos's current Enterprise Value is C$56.97 Mil.
Diagnos's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnos (TSXV:ADK) has a EV-to-OCF of -14.25 as of Sep. 20, 2026. According to the industry distribution chart, Diagnos ranks #85 out of 685 companies in the Healthcare Providers & Services industry, placing it in the top 12.4%.
Is Diagnos' EV-to-OCF too high?
Diagnos' current EV-to-OCF is -14.25. Based on the distribution chart, Diagnos ranks #85 out of 685 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Diagnos has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Diagnos' EV-to-OCF compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diagnos ranks #85 out of 685 companies for EV-to-OCF. This places Diagnos in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 8.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Healthcare Providers & Services company?
The median EV-to-OCF among Healthcare Providers & Services companies is 8.83, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median EV-to-OCF is 8.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnos's current EV-to-OCF is -14.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnos stock overvalued right now?
Diagnos (TSXV:ADK) has a current EV-to-OCF of -14.25. The current EV-to-OCF is -14.25. Diagnos' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Diagnos (TSXV:ADK), the current EV-to-OCF is -14.25 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
25GF Score
Get the complete analysis for TSXV:ADK
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:ADK has been successfully added to your 
